Date:			5/16/2024		
Your Name:			Hannatu Amaza		
Manuscript Title:			The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research]		
Mar	nuscript Number (if k	known):	ADJ-D-24-00999		
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activities		ript. "Rela of the ma e in doub os/activitions, you	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.  es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠  Ne	one	Click the tab key to add additional rows.	
			Time frame: past 36 month	S	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠  N	one		
3	Royalties or licenses	× N	one		

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:			5/16/2024		
Your Name:			Amber Niay		
Manuscript Title:			The Health Equity Scholars Program: Foster Independent Investigators in Alzheimer's Di		
Maı	nuscript Number (if k	nown):	ADJ-D-24-00999		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt. The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned."		pt. "Rela of the man e in doubt s/activition nsion, you entioned	rt for the work reported in this manuscript without time limit. For all other items, the time		
		Name al	l entities with whom you have this	Specifications/Comments (e.g., if payments were	
		relations	ship or indicate none (add rows as needed)	made to you or to your institution)	
			, h	made to you or to your matitution;	
			Time frame: Since the initial planning		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	ř I			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	r I	Time frame: Since the initial planning	Click the tab key to add additional rows.	
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for		Time frame: Since the initial planning	Click the tab key to add additional rows.	

licenses

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

ICMJE DISCLOSURE FORM			
Date: 5/16/2024			
Your Name:	Mai Seng Thao		
Manuscript Title: The Health Equity Scholars Program: Fostering Culturally Competent and Succe Independent Investigators in Alzheimer's Disease and Related Dementia Research			
Manuscript Number (if I	(nown): ADJ-D-24-00999		
content of your manuscr affected by the content indicate a bias. If you ar The author's relationship epidemiology of hyperte that medication is not m	rency, we ask you to disclose all relationships/activities/interests listed below that are related to the ipt. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be of the manuscript. Disclosure represents a commitment to transparency and does not necessarily in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  **Description** is a selection of the manuscript pertains to the manufacturers of antihypertensive medication, even if the manuscript.  **All support for the work reported in this manuscript without time limit. For all other items, the time is past 36 months.		
	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)		

		Name all entities with whom you have this selationship or indicate none (add rows as needed) Specifications/Comments (e.g., if prelationship or indicate none (add rows as needed)	=	
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None  Click the tab key to add additional rows.		
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None		
3	Royalties or licenses	None None		

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

ICMJE DISCLOSURE FORM			
Date: 5/22/2024			
Your Name:	Your Name: Joe Strong		
Manuscript Title:	Manuscript Title: The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research]		
Manuscript Number (if kn	own): ADJ-D-24-00999		
content of your manuscrip affected by the content of indicate a bias. If you are in the author's relationships, epidemiology of hypertens that medication is not men	I support for the work reported in this manuscript w	t-for-profit third parties whose interests may be not to transparency and does not necessarily (interest, it is preferable that you do so.)  xample, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	lame all entities with whom you have this elationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning	of the work	
1 All support for the	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
-	contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None None	

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:			4/23/2024		
Your Name:			Alyssa Arentoft		
Manuscript Title:			The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research		
Manuscript Number (if known):			ADJ-D-24-00999		
con affe indi The epic that	tent of your manuscricted by the content of cate a bias. If you are author's relationship demiology of hypertest medication is not mo	ipt. "Rela of the ma e in doub os/activitionsion, you entioned	ated" means any relation with for-profit or no nuscript. Disclosure represents a commitme t about whether to list a relationship/activity es/interests should be defined broadly. For a u should declare all relationships with manual in the manuscript.	/interest, it is preferable that you do so.	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	g of the work	
1	All support for the present manuscript (e.g., funding, provision		one ard of NIH/NIA U19AG024904	Issued to me through my institution	
	of study materials, medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.	
	of study materials, medical writing, article processing charges, etc.) No time limit for		Time frame: past 36 mont		
2	of study materials, medical writing, article processing charges, etc.) No time limit for	NIH/NI	Time frame: past 36 mont one MH SC2MH118473 ard of NIH/NIA U19 AG078109		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Honoraria from R13AG071313	Payment to me
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	Nih/NiA U19AG024904 Nih/NiMH SC2MH118473	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Committee Member, Women in Neuropsychology (WIN) Committee, Society for Clinical Neuropsychology (SC), APA Division 40	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	[⊠] None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:			5/16/2024		
Your Name:			Vanessa Guzman		
Manuscript Title:			The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research]		
Mai	nuscript Number (if k	(nown):	ADJ-D-24-00999		
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activiti			lated" means any relation with for-profit or no anuscript. Disclosure represents a commitmen of about whether to list a relationship/activity, dies/interests should be defined broadly. For e ou should declare all relationships with manufaction the manuscript.	vample, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th		·	ithout time limit. For all other items, the time	
			all entities with whom you have this aship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g.,		None		
	funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIH A	01AG065110 G024904 01AG082350 Time frame: past 36 month	S	
2	of study materials, medical writing, article processing charges, etc.) No time limit for	NIH A	G024904	S	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None  None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	New York Neuropsychology Group Board Member

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:			6/1/2024		
You	r Name:		Sid O'Bryant		
Manuscript Title:			The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research]		
Mar	nuscript Number (if I	known):	ADJ-D-24-00999		
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activities			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.  es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if		
that medication is not mentioned In item #1 below, report all suppo frame for disclosure is the past 36			rt for the work reported in this manuscript w	ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[⊠] No	one	Click the tab key to add additional rows.	
			Time frame: past 36 month	5	
2	Grants or contracts from any entity (if not indicated in item #1 above).	l J	one al Institute on Aging	U19AG078109	
3	Royalties or licenses	× No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	05/17/2024
Your Name:	Michael W. Weiner
Manuscript Title:	The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research]
Manuscript Number (if known):	ADJ-D-24-00999

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIH Grant: 5R01AG058676-02 NIH Grant: 2 U19 AG024904.16	Payments were made to my institution. Payments were made to my institution. Click the tab key to add additional rows.
2	Grants or contracts from	Time frame: past 36 mont	ns
	any entity (if not indicated in item #1 above).	NIH Grant: 5U2CAG060426-04  NIH Grant: 1RF1AG059009-01  NIH Grant: R33 AG062867  NIH Grant: 1R01NS119651-01  NIH Grant: RF1AG062196  NIH Grant: R56AG075744-01A1  Additional support from Department of Defense (DOD)  Additional support from: California Department of Public Health (CDPH)  Additional support from: Siemens  Additional support from: Biogen  Additional support from: Hillblom Foundation	Payments were made to my institution.  Payments were made to my institution.  Payments were made to my institution.  Payments were made to my institution.  Payments were made to my institution.  Payments were made to my institution.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Additional support from: Alzheimer's Association	Payments were made to my institution.
		Additional support from: Johnson & Johnson	Payments were made to my institution.
		Additional support from: Kevin and Connie Shanahan	Payments were made to my institution.
		Additional support from: GE	Payments were made to my institution.
		Additional support from: VUmc	Payments were made to my institution.
		Additional support from: Australian Catholic University (HBI-BHR)	Payments were made to my institution.
		Additional support from: The Stroke Foundation	Payments were made to my institution.
		Additional support from: Veterans Administration	Payments were made to my institution.
	Royalties or licenses	None     ■	
		r 1	
4	Consulting fees	□ None	
		Boxer Capital	Payment was made directly to me.
		Cerecin	Payment was made directly to me.
		Clario/BioClinica	Payment was made directly to me.
		Dementia Society of Japan	Payment was made directly to me.
		Eisai	Payment was made directly to me.
		Guidepoint	Payment was made directly to me.
		Health and Wellness Partners	Payment was made directly to me.
		Indiana U.	Payment was made directly to me.
		LCN Consulting	Payment was made directly to me.
		Merck Sharp & Dohme Corp.  Duke U.	Payment was made directly to me.
			Payment was made directly to me.
		Prova Education	Payment was made directly to me.
		T3D Therapeutics University of Southern CA (USC)	Payment was made directly to me.  Payment was made directly to me.
		WebMD	Payment was made directly to me.
		MEDA Corp.	Payment was made directly to me.
	Payment or honoraria for	None	
	lectures,	China Association for Alzheimer's Disease (CAAD)	Payment was made directly to me.
	presentations,	Taipei Medical University	Payment was made directly to me.
	speakers	Cleveland Clinic	Payment was made directly to me.
	bureaus,	AD/PD Congress	Payment was made directly to me.
	manuscript	Foundation of Learning; Health Society (Japan)	Payment was made directly to me.
	writing or	INSPIRE Project; U. Toulouse	Payment was made directly to me.
	educational	Japan Society for Dementia Research	Payment was made directly to me.
	events	Korean Dementia Society	Payment was made directly to me.
		Merck Sharp & Dohme Corp.,	Payment was made directly to me.
		National Center for Geriatrics and Gerontology (NCGG; Japan	Payment was made directly to me.
		University of Southern California (USC)	Payment was made directly to me.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	None	
7	Support for attending	None	
	meetings and/or travel	AD/PD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Cleveland Clinic	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		CTAD Congress	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Foundation of Learning; Health Society (Japan)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		INSPIRE Project; U. Toulouse	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Japan Society for Dementia Research	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Korean Dementia Society	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		Merck Sharp & Dohme Corp.,	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		National Center for Geriatrics and Gerontology (NCGG; Japan	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
		University of Southern California (USC)	Payment was made either directly to the travel accommodations provider, or reimbursed to me.
8	Patents planned, issued or pending	None	
9	Participation on	□ None	
	a Data Safety Monitoring	ADNI Scientific Advisory Board	Leadership
	Board or Advisory Board	UCSF Committee for Human Research	Committee Member
10	Leadership or fiduciary role in	None	
	other board,	UCSF Inclusion Diversity Equity & Awareness Committee	Leadership
	committee or advocacy group, paid or unpaid	Diversity Task Force of the Alzheimer's Disease Neuroimaging Initiative (ADNI)	Leadership

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
		Alzeca	Stock options held.
		Alzheon, Inc.	Stock options held.
		ALZPath	Stock options held.
		Anven	Stock options held.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	5/21/2024
Your Name:	Monica Rivera Mindt, Ph.D.
Manuscript Title:	The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research]
Manuscript Number (if known):	ADJ-D-24-00999

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning o	of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	□ None  NIA U19AG024904-16  NIA R01AG065110	Click the tab key to add additional rows.
	Time frame: past 36 months	S
Grants or contracts from any entity (if not indicated in item #1 above).	None           NIA R56AG075744           NIA R13AG071313-01           Genentech Charitable Foundation FR-008257           NIA U01AG082350           NIA U19AG078109           NIGMS SC3GM141996           NIA R01AG066471-01A1	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	relationship or indicate none (add rows as needed)  Time frame: Since the initial planning of the indicate none (add rows as needed)  All support for the present

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■	
4	Consulting fees	□ None  Harvard University Summer 2023	Payment to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Keynote Address: Rivera Mindt, M. (2023, January). On Making Neuroimaging Studies More Equitable, Inclusive, & Relevant. Annual Human Amyloid Imaging Conference; Miami, FL; January 12, 2023.  Keynote Address: Rivera Mindt, M. (2023, March). Dementia Research & Care: Increasing Access for Historically Disadvantaged Populations. South Texas Alzheimer's Conference. March 8 <sup>th</sup> , 2023  Keynote Address: Rivera Mindt, M. (2023, October). Creating more Equitable and Valid Alzheimer's Clinical Trials for the 21st Century. Annual Clinical Trials on Alzheimer's Disease Conference; Boston, MA; October 25, 2023.  Invited Speaker: M. Rivera Mindt. (2022, January.) A New Path Forward: Advancing Equity and Inclusion in Dementia Care and Research. Lefeber Winter Series on Aging, University of Texas Medical Branch at Galveston  Invited Speaker: M. Rivera Mindt (2022, October.) A Roadmap for Advancing Brain Health Equity in Science and Care; American Neurological Association Conference; Chicago, IL; October 25, 2022.  Invited Speaker: M. Rivera Mindt. (2022, May.) CDC Alzheimer's Association BOLD Public Health Center of Excellence: Sociocultural Determinants of Health – Part 2. Centers for Disease Control and Prevention: BOLD Public Health Center of Excellence on Dementia Risk Reduction (Virtual).	Payment to me
6	Payment for expert testimony	None     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■     ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	NIA U19AG024904-16 NIA R01AG065110 NIA R56AG075744 NIA R13AG071313-01 Genentech Charitable Foundation FR-008257 NIA U01AG082350 NIA U19AG078109 NIGMS SC3GM141996 NIA R01AG066471-01A1	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Data Safety & Monitoring Board (DSMB) Member  Member, Einstein/Rockefeller/Hunter CFAR (ERC-CFAR) HIV and Mental Health Scientific Working Group  Member, CDC/National Alzheimer's Project Act (NAPA) Physical Activity, Tobacco Use, and Alcohol Workgroup  Member, Centers for Disease Control and Prevention (CDC) BOLD Public Health Center of Excellence on Dementia Risk Reduction Expert Panel  Advisory Board Member, Brown University Center for Alzheimer's Disease Research Center/Carney Institute for Brain Science  Member, ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) External Advisory Board (NIH/NIA#: U19AG063911; MPIs: A. Boxer, B. Boeve, H. Rosen)  Member, Research Advisory Group, Recruitment Accelerator for Diversity in Aging Research, Cognitive Loss and Dementia (RADAR; NIH/NIA: 5R24AG06516; PI: M. Sano)  Member, University of Washington Alzheimer's Disease Research Center Advisory Board (NIH/NIA#: P50AG005136; PI: T.J. Grabowski)  Member, University of Texas Rio Grand Valley Resource Center for Minority Aging Research Advisory Board (NIH/NIA#: 5P30AG059305; MPIs: G. Maestre & S. Seshadri)	Project Title: Natives Engaged in Alzheimer's Research (NEAR); Grant # 1P01AG066584-01A1 (PI: D. Buchwald)

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Member, National Centralized Repository for ADRD (NCRAD) Executive Committee (NIH/NIA#: U24AG021886; PI: T. Foroud)  Member, University of California, San Francisco Alzheimer's Disease Research Center Advisory Board (NIH/NIA: P30AG062422Project-05; PI: G. Ravinovici)  Member, Mayo Clinic Alzheimer's Disease Research Center Advisory Board (NIH/NIA#: P50G016574; PI: R. Petersen)		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None  Harlem Community and Academic Partnership	Treasurer	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			
$\boxtimes$	☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	7/3/2024
Your Name:	Ozioma C. Okonkwo
Manuscript Title:	The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research
Manuscript Number (if known):	ADJ-D-24-00999
• • • • • • • • • • • • • • • • • • • •	e ask you to disclose all relationships/activities/interests listed below that are related to the

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		Grants to my institution  Click the tab key to add additional rows.
	contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	International Neuropsychological Society	Treasurer

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			